SaNOtize’s key innovation is the development of solutions that locally release nitric oxide (NO) in concentrations with potential antimicrobial effects against viruses, bacteria, and fungi.

Nitric oxide is a molecule that naturally occurs in our bodies. For decades, it has been approved to treat “blue baby syndrome” in hospitals, delivered through pressurized gas cylinders and specialized inhalation devices. While its antimicrobial properties were well-documented, designing a safe and convenient method to deliver nitric oxide for everyday use remained a major challenge.

Recognizing NO’s potential as a topical antimicrobial, the founders of SaNOtize developed breakthrough technology to stabilize and deliver it in precise doses at the site of infection. Their proprietary platform, Nitric Oxide Releasing Solution (NORS™), allows NO to be used as a targeted, therapeutic antimicrobial for respiratory and skin-related infections.

SaNOtize’s patented NORS™ technology is the foundation of a growing pipeline of anti-infective products with the potential to improve the quality of life for millions. It enables the development of gels, creams, and liquids designed to address a broad spectrum of viral, bacterial, and fungal infections.